Clinical Trial Update: Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing treat-and-extend with 0.5 mg ranibizumab versus monthly 0.5 mg ranibizumab for macular degeneration; trial completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Charles C Wykoff, PhD, MD | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2017-10-20